Background. Oxidative processes might increase in patients with end-stage renal disease (ESRD) according to the current literature. Oxidative stress (OS) is a risk factor of atherosclerosis and cardiovascular complications, which are major causes of mortality among ESRD patients. Haemodialysis (HD) is life-saving procedure, nevertheless it is an active chronic inflammatory status that could augment cardiovascular disease and increase mortality. Gum Arabic (GA) has been claimed to act as an antioxidant and anti-inflammatory agent in experimental studies and clinical trials. Therefore, we assumed GA supplementation among haemodialysis patients would reduce oxidative stress and consequently reduce the state of chronic inflammatory activation associated with haemodialysis. Methods. Forty end-stage renal failure (ESRF) patients aged 18–80 years who were on regular haemodialysis in Arif Renal Center, Omdurman, Sudan, were recruited. All recruited patients met the inclusion criteria and signed informed consent prior to enrolment. The patients received 30 g/day of GA for 12 weeks. C-reactive protein (CRP) and complete blood count (CBC) were measured as baseline and monthly. Total antioxidant capacity (TAC) and oxidative stress marker malondialdehyde (MDA) levels were measured before and after GA intake. Ethical approval from the National Medicines and Poisons Board was obtained. Results. Gum Arabic significantly augmented total antioxidant capacity level (P<0.001) (95% CI, 0.408–0.625) and also attenuated oxidative marker MDA and C-reactive protein (P<0.001). Conclusions. GA has revealed potent antioxidative and anti-inflammatory properties in haemodialysis patients. Oral digestion of GA (30 g/day) decreased oxidative stress and inflammatory markers among haemodialysis patients. Trial registration. ClinicalTrials.gov Identifier: NCT03214692, registered 11 July 2017 (prospective registration).

Objectives: To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients. To study the effect of GA on the level of cytokines, TNFα, IL8, IL6 IL10, CRP and the viral load. Secondary outcomes will be the effect of GA oral intake on mortality rate and days of hospital admission. Trial design: Quadruple blind, randomized placebo-controlled clinical trial Phase II & III. Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio) superiority trial of oral GA among seropositive COVID-19 patients. Participants: Inclusion criteria: COVID-19 infected (newly diagnosed) as proved by real-time PCR within 72 hours of PCR. Age 8-90 years Both genders Exclusion criteria: Intubated patients on parenteral treatment Allergy to Gum Arabic The study will be conducted in COVID Isolation Centres and

No abstract

No abstract

Background: Most blood collection bags contain 63 mL CPDA anticoagulant which is sufficient to anticoagulant and ensures the viability of blood cells in 450 mL±10% blood for up to 28-35 days when the blood is stored at 2-8°C. Prolonged storage of blood leads to alteration in cells hematologically which may lose viability with time. Aim: The study was conducted to determine the effect of storage on CPDA-1 for varying periods on some hematological parameters. Materials and methods: The study was conducted on blood donated by 30 healthy volunteer donors. Effect of storage was analyzed at 1, 7, 14, 21and 28 days intervals. Hematological parameters were measured using Mindary PS 300 hematology analyzer. Results:There is a highly significant increase in hemoglobin concentration, packed cell volume (P.C.V. %), MCV, and also a decrease in lymphocyte, granulocyte, and platelet count. The results also showed an insignificant decrease in total white blood cell count. Conclusion: There are degenerative changes observed in blood parameters in samples collected in citrate phosphate dextrose adenine (CPDA-1).